Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients (NCT07315139) | Clinical Trial Compass
CompletedNot Applicable
Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients
Egypt42 participantsStarted 2023-02-01
Plain-language summary
This study aimed to determine the impact of Pentoxifylline on inflammatory biomarkers and the progression of chronic kidney disease in non-diabetic patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ˃ 18 years old.
* Both sexes.
* Patients with chronic kidney disease (CKD) stages G3, G4.
* Patients with proteinuria \< 1 g.
Exclusion Criteria:
* Patients who are terminally ill.
* Patients with Diabetes mellitus.
* Patients with proteinuria \> 1 g.
* Patients with a history of hemodialysis.
* Patients with active infection or hospitalized.
* Patients with recent cerebral and /or retinal Hemorrhage.
* Patients taking warfarin or theophylline-containing drugs.
* women who are taking oral contraceptives, pregnant, or lactating
* Patients with a history of adverse reactions to Pentoxifylline.
* Patients with polycystic kidney disease.
* Patients with obstructive uropathy.